Department of Haematology, University Hospital of Nîmes, Nîmes, France.
Faculty of Pharmaceutical and Biological Sciences, University of Montpellier, Montpellier, France.
J Thromb Thrombolysis. 2023 Aug;56(2):351-354. doi: 10.1007/s11239-023-02836-4. Epub 2023 Jun 10.
Over the last decade, the concept of Clonal haematopoiesis of undetermined potential (CHIP) has emerged. Low frequency somatic mutations in hematopoietic cells can occur with age and might allow formation of clones in individuals with no characterized haematological pathology. These CHIP mutations are associated with an increased risk of cancer or atherothrombosis, and their prevalence are more and more studied in pathologies with an inflammatory component. In our study, we analysed, by next generation sequencing, the prevalence of CHIP mutation in 94 patients with deep venous thrombosis (DVT), distinguishing two clinical phenotypes: provoked distal and non-provoked proximal DVTs. We show that there is no difference in CHIP prevalence between these two groups, nor with a matched-aged control group. The number of mutation per patients and the affected genes remain also the same between the three groups. Consequently and despite the relative small number of patients in each cohort, it seems that CHIP is not a strong concern in venous thromboembolism.
在过去的十年中，出现了未确定潜能的克隆性造血（CHIP）的概念。随着年龄的增长，造血细胞中的低频体细胞突变可能会导致无特征性血液病理学个体的克隆形成。这些 CHIP 突变与癌症或动脉血栓形成的风险增加有关，其在具有炎症成分的病理学中的患病率越来越受到研究。在我们的研究中，我们通过下一代测序分析了 94 例深静脉血栓形成（DVT）患者的 CHIP 突变患病率，区分了两种临床表型：诱发性远端和非诱发性近端 DVT。我们表明，这两组之间的 CHIP 患病率没有差异，与年龄匹配的对照组也没有差异。三组之间每个患者的突变数量和受影响的基因也相同。因此，尽管每个队列中的患者数量相对较少，但 CHIP 在静脉血栓栓塞症中似乎不是一个主要关注点。
